Anthony T Vesco1,2, Jennifer Lehmann3, Barbara L Gracious1,4, L Eugene Arnold1, Andrea S Young1, Mary A Fristad1,2. 1. 1 Department of Psychiatry and Behavioral Health, The Ohio State University Wexner Medical Center , Columbus, Ohio. 2. 2 Department of Psychology, The Ohio State University , Columbus, Ohio. 3. 3 Department of Psychology, Case Western Reserve University , Cleveland, Ohio. 4. 4 Center for Innovation in Pediatric Practice, The Research Institute at Nationwide Children's Hospital , Nationwide Children's Hospital, Columbus, Ohio.
Abstract
OBJECTIVES: Therapeutic benefits of omega-3 fatty acids (Ω3) for mood disorders, psychosis, and anxiety have been reported in the literature. The purpose of the present article is to provide a literature review of Ω3 supplementation for affective disorders and to illustrate the benefits of Ω3 with a case presentation of a young girl with a history of bipolar disorder-type 1 with psychotic features and generalized anxiety disorder. METHODS: Reviewed literature includes treatment studies of the impact of Ω3 on child mood disorders supplemented by review of meta-analyses within the adult mood disorders literature. The subject of this case report participated in 11 in-depth diagnostic and functional assessments over 5 years as part of an unrelated study. Three years were presupplementation and 2 years were with supplementation with no other medication changes, thus making a naturalistic multiple-baseline single-subject experiment. RESULTS: Augmentation over a 2 year period was notable for clinically significant and sustained improvement in depressive, manic, and psychotic symptoms. CONCLUSION: Ω3 supplementation may be a safe, adjunct intervention for treating bipolar disorder in children and adolescents, even in the presence of psychotic and anxious features. The 2 year follow-up in this case offers hope of an accumulating and enduring benefit. Further research into mechanisms of Ω3 action and of combination treatment with other well-known interventions for mood disorders would be beneficial.
OBJECTIVES: Therapeutic benefits of omega-3 fatty acids (Ω3) for mood disorders, psychosis, and anxiety have been reported in the literature. The purpose of the present article is to provide a literature review of Ω3 supplementation for affective disorders and to illustrate the benefits of Ω3 with a case presentation of a young girl with a history of bipolar disorder-type 1 with psychotic features and generalized anxiety disorder. METHODS: Reviewed literature includes treatment studies of the impact of Ω3 on childmood disorders supplemented by review of meta-analyses within the adult mood disorders literature. The subject of this case report participated in 11 in-depth diagnostic and functional assessments over 5 years as part of an unrelated study. Three years were presupplementation and 2 years were with supplementation with no other medication changes, thus making a naturalistic multiple-baseline single-subject experiment. RESULTS: Augmentation over a 2 year period was notable for clinically significant and sustained improvement in depressive, manic, and psychotic symptoms. CONCLUSION: Ω3 supplementation may be a safe, adjunct intervention for treating bipolar disorder in children and adolescents, even in the presence of psychotic and anxious features. The 2 year follow-up in this case offers hope of an accumulating and enduring benefit. Further research into mechanisms of Ω3 action and of combination treatment with other well-known interventions for mood disorders would be beneficial.
Authors: Marlene P Freeman; Joseph R Hibbeln; Katherine L Wisner; John M Davis; David Mischoulon; Malcolm Peet; Paul E Keck; Lauren B Marangell; Alexandra J Richardson; James Lake; Andrew L Stoll Journal: J Clin Psychiatry Date: 2006-12 Impact factor: 4.384
Authors: G Paul Amminger; Miriam R Schäfer; Konstantinos Papageorgiou; Claudia M Klier; Sue M Cotton; Susan M Harrigan; Andrew Mackinnon; Patrick D McGorry; Gregor E Berger Journal: Arch Gen Psychiatry Date: 2010-02
Authors: Nilufar Mossaheb; Miriam R Schäfer; Monika Schlögelhofer; Claudia M Klier; Susan M Cotton; Patrick D McGorry; G Paul Amminger Journal: Schizophr Res Date: 2013-06-15 Impact factor: 4.939
Authors: L Eugene Arnold; Mary A Fristad; Barbara L Gracious; Jeanette M Johnstone; Bonnie J Kaplan; Charles W Popper; Julia J Rucklidge Journal: Prim Care Companion CNS Disord Date: 2016-04-28
Authors: B N Yamaja Setty; Suhita Gayen Betal; Robin E Miller; Dawn S Brown; Maureen Meier; Michele Cahill; Norma B Lerner; Nataly Apollonsky; Marie J Stuart Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2019-05-10 Impact factor: 4.006
Authors: Lisa M Christian; Andrea S Young; Amanda M Mitchell; Martha A Belury; Barbara L Gracious; L Eugene Arnold; Mary A Fristad Journal: PLoS One Date: 2017-04-05 Impact factor: 3.240
Authors: Sarah J Carlson; Alison A O'Loughlin; Lorenzo Anez-Bustillos; Meredith A Baker; Nicholas A Andrews; Georgia Gunner; Duy T Dao; Amy Pan; Prathima Nandivada; Melissa Chang; Eileen Cowan; Paul D Mitchell; Kathleen M Gura; Michela Fagiolini; Mark Puder Journal: Front Neurosci Date: 2019-02-25 Impact factor: 4.677
Authors: Robert M Post; Benjamin I Goldstein; Boris Birmaher; Robert L Findling; Benicio N Frey; Melissa P DelBello; David J Miklowitz Journal: J Affect Disord Date: 2020-03-06 Impact factor: 4.839